Long COVID/PASC

Advocacy

(Advertisement)

AAPM&R is Calling for a Comprehensive National Plan to Address the Needs of Millions Suffering from Long COVID

According to two publications from the Journal of the American Medical Association, ten to thirty percent of individuals who had COVID-19 reported at least one persistent symptom up to six months after the virus left their bodies. That means 3 to 10 million Americans are experiencing symptoms of Long COVID or Post-Acute Sequelae of SARS-CoV-2 infection (PASC), which are varied and ongoing, including neurological challenges, cognitive problems such as brain fog, shortness of breath, fatigue, pain, and mobility issues.

In 2021, AAPM&R called on President Joe Biden and Congress to gear up for the next coronavirus crisis by preparing and implementing a comprehensive national plan focused on meeting the needs of millions of individuals suffering from the long-term symptoms of COVID-19, and help them regain quality of life and return to being active members of their communities. The plan must include a commitment to three major components:

  • Resources to build necessary infrastructure to meet this crisis
  • Equitable access to care for patients
  • Research to advance medical understanding of Long COVID

PM&R physicians are uniquely qualified to help guide the multidisciplinary effort needed to develop a plan for this crisis. As a specialty, physiatrists are investigators, team leaders and problem solvers. PM&R physicians see the whole patient AND the whole picture of the rehabilitation ecosystem. Physiatrists are exactly what this crisis needs. Learn more about our Multidisciplinary PASC Collaborative, launched in March 2021, which is working on quality improvement initiatives.

AAPM&R Advocacy, Healthcare Collaborations and Partnerships, and Customized Resources to Support PM&R During This Crisis

AAPM&R is working to ensure PM&R is part of the national conversation about healthcare amidst COVID-19 and advocating for the federal support, legislation, regulation relief and resources that physiatrists need now. One way we are doing this is through our partnerships and collaborations with other specialty societies. The Academy continuously works to represent PM&R through these collaborations, and it is through these partnerships that we are able to discuss and share a variety of resources with you that you critically need.

Stay Up-to-Date

DEA and HHS Releases Second Temporary Extension for COVID-19 Telehealth Flexibilities

Oct 18, 2023

On September 29, the Drug Enforcement Agency (DEA) and Health and Human Services (HHS) jointly announced a secondary temporary extension allowing telehealth flexibilities for the prescription of controlled substances.

  • The full set of telemedicine flexibilities regarding prescription of controlled medications as were in place during the COVID-19 PHE will remain in place through December 31, 2024.
  • Additionally, this extension authorizes all DEA-registered practitioners to prescribe schedule II–V controlled medications via telemedicine through December 31, 2024, whether or not the patient and practitioner established a telemedicine relationship on or before November 11, 2023. In other words, the grace period provided in the first temporary rule is effectively subsumed by this second temporary rule, which continues the extension of the current flexibilities for all practitioner-patient relationships—not just those established on or before November 11, 2023—until the end of 2024.

The secondary temporary extension now aligns with the broader telehealth flexibilities established under the Consolidated Appropriations Act (CAA), 2023 that are set to expire on December 31, 2024. For more information, please visit the Academy’s webpage End to Public Health Emergency Waivers or contact healthpolicy@aapmr.org with any questions.